(Q62041711)

English

Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma

clinical trial

Statements

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) (English)
0 references
0 references
0 references
0 references
28 November 2018
0 references
November 2020
0 references
264
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
16 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit